Publication

Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors

Carbo, M. J. G., Spoorenberg, A., Maas, F., Brouwer, E., Bos, R., Bootsma, H., van der Veer, E., Wink, F. & Arends, S., 24-Apr-2018, In : PLoS ONE. 13, 4, 12 p., e0196281.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Carbo, M. J. G., Spoorenberg, A., Maas, F., Brouwer, E., Bos, R., Bootsma, H., ... Arends, S. (2018). Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors. PLoS ONE, 13(4), [e0196281]. https://doi.org/10.1371/journal.pone.0196281

Author

Carbo, Marlies J G ; Spoorenberg, Anneke ; Maas, Fiona ; Brouwer, Elisabeth ; Bos, Reinhard ; Bootsma, Hendrika ; van der Veer, Eveline ; Wink, Freke ; Arends, Suzanne. / Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors. In: PLoS ONE. 2018 ; Vol. 13, No. 4.

Harvard

Carbo, MJG, Spoorenberg, A, Maas, F, Brouwer, E, Bos, R, Bootsma, H, van der Veer, E, Wink, F & Arends, S 2018, 'Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors', PLoS ONE, vol. 13, no. 4, e0196281. https://doi.org/10.1371/journal.pone.0196281

Standard

Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors. / Carbo, Marlies J G; Spoorenberg, Anneke; Maas, Fiona; Brouwer, Elisabeth; Bos, Reinhard; Bootsma, Hendrika; van der Veer, Eveline; Wink, Freke; Arends, Suzanne.

In: PLoS ONE, Vol. 13, No. 4, e0196281, 24.04.2018.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Carbo MJG, Spoorenberg A, Maas F, Brouwer E, Bos R, Bootsma H et al. Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors. PLoS ONE. 2018 Apr 24;13(4). e0196281. https://doi.org/10.1371/journal.pone.0196281


BibTeX

@article{b432e2bd2dd746e5a9557b858c7e7932,
title = "Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors",
abstract = "BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cornerstone of conventional treatment for AS. However little is known about concomitant NSAID use during treatment (with TNF-α inhibitors) in daily clinical practice.METHODS AND FINDINGS: Consecutive patients from the GLAS cohort were included. NSAID use and ASAS-NSAID index were evaluated at group level and at individual patient level during 52 weeks of follow-up. Analyses were stratified for treatment regimen. Generalized estimating equations (GEE) was used to evaluate NSAID use in relation to assessments of disease activity over time. In patients starting TNF-α inhibitors (n = 254), 79{\%} used NSAIDs at baseline and this proportion decreased significantly to 38{\%} at 52 weeks. ASAS-NSAID index also decreased significantly from median 65 to 0. In patients on conventional treatment (n = 139), 74{\%} used NSAIDs at baseline with median ASAS-NSAID index of 50 and this remained stable during follow-up. At each follow-up visit, approximately half of the patients changed their type or dose of NSAIDs. GEE analysis over time showed that NSAID use was associated with AS disease activity score (p<0.05). This relation was more pronounced in patients treated with TNF-α inhibitors compared to conventional treatment (B = 0.825 vs. B = 0.250).CONCLUSIONS: In this observational cohort of established AS patients, there was no difference in baseline NSAID use between patients with and without indication for TNF-α inhibitors. NSAID use decreased significantly after starting TNF-α inhibitors. During conventional treatment, NSAID use remained stable at group level. However, NSAID use changed frequently at individual patient level and was significantly associated with disease activity.",
keywords = "NONSTEROIDAL ANTIINFLAMMATORY DRUGS, AXIAL SPONDYLOARTHRITIS, RADIOGRAPHIC PROGRESSION, ASAS RECOMMENDATIONS, ACTIVITY INDEX, DESIR COHORT, TRIAL",
author = "Carbo, {Marlies J G} and Anneke Spoorenberg and Fiona Maas and Elisabeth Brouwer and Reinhard Bos and Hendrika Bootsma and {van der Veer}, Eveline and Freke Wink and Suzanne Arends",
year = "2018",
month = "4",
day = "24",
doi = "10.1371/journal.pone.0196281",
language = "English",
volume = "13",
journal = "PLOS-One",
issn = "1932-6203",
publisher = "PUBLIC LIBRARY SCIENCE",
number = "4",

}

RIS

TY - JOUR

T1 - Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors

AU - Carbo, Marlies J G

AU - Spoorenberg, Anneke

AU - Maas, Fiona

AU - Brouwer, Elisabeth

AU - Bos, Reinhard

AU - Bootsma, Hendrika

AU - van der Veer, Eveline

AU - Wink, Freke

AU - Arends, Suzanne

PY - 2018/4/24

Y1 - 2018/4/24

N2 - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cornerstone of conventional treatment for AS. However little is known about concomitant NSAID use during treatment (with TNF-α inhibitors) in daily clinical practice.METHODS AND FINDINGS: Consecutive patients from the GLAS cohort were included. NSAID use and ASAS-NSAID index were evaluated at group level and at individual patient level during 52 weeks of follow-up. Analyses were stratified for treatment regimen. Generalized estimating equations (GEE) was used to evaluate NSAID use in relation to assessments of disease activity over time. In patients starting TNF-α inhibitors (n = 254), 79% used NSAIDs at baseline and this proportion decreased significantly to 38% at 52 weeks. ASAS-NSAID index also decreased significantly from median 65 to 0. In patients on conventional treatment (n = 139), 74% used NSAIDs at baseline with median ASAS-NSAID index of 50 and this remained stable during follow-up. At each follow-up visit, approximately half of the patients changed their type or dose of NSAIDs. GEE analysis over time showed that NSAID use was associated with AS disease activity score (p<0.05). This relation was more pronounced in patients treated with TNF-α inhibitors compared to conventional treatment (B = 0.825 vs. B = 0.250).CONCLUSIONS: In this observational cohort of established AS patients, there was no difference in baseline NSAID use between patients with and without indication for TNF-α inhibitors. NSAID use decreased significantly after starting TNF-α inhibitors. During conventional treatment, NSAID use remained stable at group level. However, NSAID use changed frequently at individual patient level and was significantly associated with disease activity.

AB - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cornerstone of conventional treatment for AS. However little is known about concomitant NSAID use during treatment (with TNF-α inhibitors) in daily clinical practice.METHODS AND FINDINGS: Consecutive patients from the GLAS cohort were included. NSAID use and ASAS-NSAID index were evaluated at group level and at individual patient level during 52 weeks of follow-up. Analyses were stratified for treatment regimen. Generalized estimating equations (GEE) was used to evaluate NSAID use in relation to assessments of disease activity over time. In patients starting TNF-α inhibitors (n = 254), 79% used NSAIDs at baseline and this proportion decreased significantly to 38% at 52 weeks. ASAS-NSAID index also decreased significantly from median 65 to 0. In patients on conventional treatment (n = 139), 74% used NSAIDs at baseline with median ASAS-NSAID index of 50 and this remained stable during follow-up. At each follow-up visit, approximately half of the patients changed their type or dose of NSAIDs. GEE analysis over time showed that NSAID use was associated with AS disease activity score (p<0.05). This relation was more pronounced in patients treated with TNF-α inhibitors compared to conventional treatment (B = 0.825 vs. B = 0.250).CONCLUSIONS: In this observational cohort of established AS patients, there was no difference in baseline NSAID use between patients with and without indication for TNF-α inhibitors. NSAID use decreased significantly after starting TNF-α inhibitors. During conventional treatment, NSAID use remained stable at group level. However, NSAID use changed frequently at individual patient level and was significantly associated with disease activity.

KW - NONSTEROIDAL ANTIINFLAMMATORY DRUGS

KW - AXIAL SPONDYLOARTHRITIS

KW - RADIOGRAPHIC PROGRESSION

KW - ASAS RECOMMENDATIONS

KW - ACTIVITY INDEX

KW - DESIR COHORT

KW - TRIAL

U2 - 10.1371/journal.pone.0196281

DO - 10.1371/journal.pone.0196281

M3 - Article

C2 - 29689112

VL - 13

JO - PLOS-One

JF - PLOS-One

SN - 1932-6203

IS - 4

M1 - e0196281

ER -

ID: 59045631